Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Reetta VirtakoivuJenna H RannikkoMiro ViitalaFelix C VauraAkira TakedaTapio LönnbergJussi KoivunenPanu M JaakkolaAnnika PasanenShishir ShettyMaja J A de JongeDebbie G J RobbrechtYuk Ting MaTanja SkyttäAnna R MinchomSirpa JalkanenMatti K KarvonenJami MandelinPetri BonoMaija HollménPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our results reveal a nonredundant role played by the receptor Clever-1 in suppressing adaptive immune cells in humans. We provide evidence that targeting macrophage scavenging activity can promote an immune switch, potentially leading to intratumoral proinflammatory responses in patients with metastatic cancer.